Evidence map›Paper›PMID 34324403›Full record

ArticleJCO oncology practice2022

Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes.

David E Gerber, Valerie L Clark, Thomas Y Sheffield, M Shaalan Beg, Yang Xie, M E Blair Holbein, Celette Sugg Skinner, Simon J Craddock Lee, Erin L Williams

Abstract read
In one paragraph

Article in JCO oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David E GerberDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-7812-6741
Valerie L ClarkHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0003-2277-4296
Thomas Y SheffieldDepartment of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0001-9073-6334
M Shaalan BegDivision of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-3754-6627
Yang XieHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0001-9456-1762
M E Blair HolbeinDepartment of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX.
Celette Sugg SkinnerHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-2535-4476
Simon J Craddock LeeHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0001-6345-1237
Erin L WilliamsHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0003-4357-4111

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
Development of New Cancer Treatments and InvestigatorsK24CA201543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GERBER, DAVID ERIC · 2016 to 2020
$737k
NCATS NIH HHS UL1 TR001105NCI NIH HHS K24 CA201543NCI NIH HHS P30 CA142543
6 · The paper itself

Abstract

purposeThe COVID-19 pandemic has led to profound changes in clinical research, including remote consent, telehealth, off-site procedures, shipment of therapy, and remote study monitoring. We assessed longitudinal perceptions of these adjustments among clinical research professionals.

methodsWe distributed an anonymous survey assessing experiences, perceptions, and recommendations regarding COVID-19-related clinical research adjustments to cancer clinical research office personnel in May 2020 and again in November 2020. Responses were compared using Fisher's exact and Mann-Whitney U tests.

resultsA total of 90 of 102 invited research personnel (88%) responded. Fifty-three (59%) reported participating in both initial and follow-up surveys. The proportion of respondents reporting personal experience with COVID-19-related adjustments increased over time, particularly for remote initial consent (29%

conclusionMore than 6 months into the global pandemic, perceptions of COVID-19-related clinical research changes remain favorable. Experienced individuals are more likely to recommend that these changes continue in the future.

Indexed as

COVID-19TelemedicineAttitudeHumansPandemicsSARS-CoV-2

Identifiers

PMID34324403
PMCPMC8757963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.